Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Rheumatology · Macrophage Activation Syndrome

Complications: Understanding Macrophage Activation Syndrome (MAS)

At a Glance

Macrophage Activation Syndrome (MAS) is a severe medical emergency in Adult-onset Still's Disease where immune cells attack healthy tissue. Warning signs include a constant unremitting fever, sudden bruising, extreme fatigue, and rapidly dropping blood counts requiring immediate treatment.

While most symptoms of Adult-onset Still’s Disease (AOSD) are painful and disruptive, there is one complication that requires immediate medical attention: Macrophage Activation Syndrome (MAS). Understanding MAS is not about living in fear; it is about knowing the warning signs so you can act quickly if they appear.

What are Macrophages?

Macrophages are essential cells in your innate immune system. Their name literally means “big eaters,” and their job is to find and destroy invaders like bacteria or dead cells [1]. In MAS, these cells—along with other immune cells—go into “overdrive.” Instead of protecting you, they begin to attack your own healthy tissues and blood cells, creating a massive cytokine storm [2][3].

Recognizing the Warning Signs

In a typical AOSD flare, your labs might show very high white blood cell counts and high inflammation markers. MAS is tricky because it can cause these numbers to suddenly “flip” in ways that might look like improvement but are actually signs of danger [4][5].

Physical Warning Signs (When to Seek Emergency Care):

  • Constant, Unremitting Fever: Instead of the classic AOSD pattern (where the fever spikes once a day and then returns to normal), an MAS fever is unrelenting and remains high all day, often unresponsive to fever-reducing drugs [6].
  • Sudden Bruising or Bleeding: Because your blood platelets are dropping dangerously low, you may notice unexplained bruises, nosebleeds, or bleeding gums [4].
  • Confusion or Lethargy: MAS can affect your central nervous system, leading to extreme fatigue, confusion, or difficulty staying awake [1].

Laboratory Warning Signs:

  • Crashing Blood Counts: A sudden drop in your white blood cells, red blood cells (anemia), or platelets (thrombocytopenia) while you still feel very sick is a major red flag [4][7].
  • Extreme Ferritin Spikes: While ferritin is high in AOSD, in MAS it can skyrocket to extraordinary levels (often above 5,000 or 10,000 ng/mL) [8][9].
  • Liver and Organ Changes: Massive spikes in liver enzymes (AST/ALT) or high levels of fats in the blood (triglycerides) [10][11].

How MAS Changes Treatment

If your doctor suspects MAS, the treatment strategy shifts from “managing a flare” to “extinguishing a fire.” The goal is to shut down the immune hyper-response as quickly as possible.

  1. High-Dose Steroids: Large doses of intravenous (IV) corticosteroids are often the first line of defense to stabilize the system [12][2].
  2. Targeted Biologics: Doctors often use medications that block the specific cytokines driving the storm. Anakinra (an IL-1 inhibitor) is frequently used, often at higher doses than for standard AOSD [13][14].
  3. Advanced Blockade: For severe cases, a newer medication called Emapalumab may be used. It targets Interferon-gamma (IFN-γ), another “bad actor” cytokine that drives macrophage overactivity [15][16].

The Importance of the “MS-Score”

Because MAS can look like a normal AOSD flare, doctors may use a tool called the MS-Score (or MAS-Score). This scoring system helps them identify MAS earlier than older diagnostic methods, allowing for life-saving treatment to start sooner [6][17].

If you feel your symptoms are changing or you are experiencing extreme fatigue, bruising, or constant fevers, contact your rheumatologist immediately or go to the emergency room. Early intervention is the most effective way to manage MAS [18][19].

Common questions in this guide

What is Macrophage Activation Syndrome (MAS) in AOSD?
MAS is a severe complication of Adult-onset Still's Disease where immune cells, called macrophages, become overactive. Instead of fighting infections, they attack your own healthy tissues and blood cells, causing a dangerous cytokine storm.
How is an MAS fever different from a normal AOSD fever?
A typical Adult-onset Still's Disease fever spikes once a day and then returns to normal. In contrast, an MAS fever is constant, unremitting, and often does not respond to standard fever-reducing medications.
What lab results suggest I might have Macrophage Activation Syndrome?
Key laboratory warning signs for MAS include a sudden drop in white blood cells, red blood cells, or platelets while you still feel very sick. Extreme spikes in ferritin (often above 5,000 ng/mL) and elevated liver enzymes are also major red flags.
How is Macrophage Activation Syndrome treated?
Treatment for MAS focuses on quickly shutting down the immune hyper-response. This typically involves high-dose intravenous steroids and targeted biologic medications like Anakinra or Emapalumab to block the cytokines driving the storm.
What is the MS-Score for MAS?
The MS-Score is a specialized diagnostic scoring system that doctors use to identify Macrophage Activation Syndrome early. Because MAS can look similar to a normal disease flare, this tool helps doctors recognize the danger signs and start life-saving treatments sooner.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current risk for MAS based on my IL-18 and ferritin levels?
  2. 2.If my blood counts (like platelets or white blood cells) start to drop while my inflammation is high, is that a sign of MAS?
  3. 3.Is my fever still following a 'quotidian' (daily) pattern, or has it become constant, which might indicate MAS?
  4. 4.If MAS is suspected, will we move directly to targeted treatments like Anakinra (IL-1 inhibitor) or Emapalumab (IFN-gamma inhibitor)?
  5. 5.What are the specific 'red flag' lab values in my report that should trigger an emergency call to your office?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Recent advances and evolving concepts in Still's disease.

    Ruscitti P, Cantarini L, Nigrovic PA, et al.

    Nature reviews. Rheumatology 2024; (20(2)):116-132 doi:10.1038/s41584-023-01065-6.

    PMID: 38212542
  2. 2

    Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.

    Bindoli S, De Matteis A, Mitrovic S, et al.

    Annals of the rheumatic diseases 2024; (83(12)):1731-1747 doi:10.1136/ard-2024-225854.

    PMID: 39317415
  3. 3

    The pathophysiology of hemophagocytic lympho-histiocytosis (HLH) syndrome and insights from animal models.

    Mukherjee S, Kumar P

    Clinical and experimental immunology 2025; (219(1)) doi:10.1093/cei/uxaf036.

    PMID: 40435290
  4. 4

    Macrophage Activation Syndrome.

    Nigrovic PA

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(4)):367-379 doi:10.1002/art.43052.

    PMID: 39491365
  5. 5

    Risk of macrophage activation syndrome in patients with adult-onset Still's disease with skin involvement: A retrospective cohort study.

    Ding Y, Tang S, Li S, et al.

    Journal of the American Academy of Dermatology 2021; (85(6)):1503-1509 doi:10.1016/j.jaad.2021.02.005.

    PMID: 33556412
  6. 6

    [Assessment of MS-Score and HScore in timeliness of diagnosis of macrophage activation syndrome associated with adult-onset Still's disease].

    Peng Z, Gao XM, Zhou S, et al.

    Zhonghua yi xue za zhi 2022; (102(28)):2210-2214 doi:10.3760/cma.j.cn112137-20220321-00602.

    PMID: 35872586
  7. 7

    A Novel Therapy for a Rare Condition: Continuous Anakinra Infusion for a Patient With Macrophage Activation Syndrome.

    Gullickson M, Nichols L, Scheibe M

    Cureus 2023; (15(8)):e42968 doi:10.7759/cureus.42968.

    PMID: 37667692
  8. 8

    Hyperferritinemia: Important Differentials for the Rheumatologists.

    Kaur M, Lo SWS, Liu Y, Yip K

    Cureus 2024; (16(9)):e68588 doi:10.7759/cureus.68588.

    PMID: 39371829
  9. 9

    Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.

    Ruscitti P, Rago C, Breda L, et al.

    Clinical rheumatology 2017; (36(12)):2839-2845 doi:10.1007/s10067-017-3830-3.

    PMID: 28914368
  10. 10

    Characterization of Patients with Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis.

    Rogowska J, Kubicka J, Grabowska M, et al.

    Clinical rheumatology 2025; (44(5)):2023-2029 doi:10.1007/s10067-025-07420-0.

    PMID: 40146446
  11. 11

    Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients.

    Wafa A, Hicham H, Naoufal R, et al.

    Clinical rheumatology 2022; (41(7)):2021-2033 doi:10.1007/s10067-022-06055-9.

    PMID: 35179662
  12. 12

    Macrophage Activation Syndrome Associated with Adult-onset Still's Disease Successfully Treated with Plasma Exchange and Canakinumab: A Case Report.

    Kiyohara W, Fujita Y, Hatta M, et al.

    Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.6642-25.

    PMID: 41621874
  13. 13

    Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.

    Mehta P, Cron RQ, Hartwell J, et al.

    The Lancet. Rheumatology 2020; (2(6)):e358-e367 doi:10.1016/S2665-9913(20)30096-5.

    PMID: 32373790
  14. 14

    Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.

    Monteagudo LA, Boothby A, Gertner E

    ACR open rheumatology 2020; (2(5)):276-282 doi:10.1002/acr2.11135.

    PMID: 32267081
  15. 15

    Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: case report and review of the literature.

    Gabr JB, Liu E, Mian S, et al.

    Annals of translational medicine 2020; (8(14)):887 doi:10.21037/atm-20-3127.

    PMID: 32793731
  16. 16

    Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.

    Lounder DT, Bin Q, de Min C, Jordan MB

    Blood advances 2019; (3(1)):47-50 doi:10.1182/bloodadvances.2018025858.

    PMID: 30617216
  17. 17

    Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.

    Wang R, Li T, Ye S, et al.

    Annals of the rheumatic diseases 2021; (80(9)):e145 doi:10.1136/annrheumdis-2019-216286.

    PMID: 31611222
  18. 18

    Early identification of macrophage activation syndrome in adult-onset Still's disease: a case report and literature review.

    Long T, Xu J, Lin BZ, Li SG

    Frontiers in medicine 2025; (12()):1498928 doi:10.3389/fmed.2025.1498928.

    PMID: 39931557
  19. 19

    Reactivation of Parvovirus B19 Infection: An Uncommon Trigger of Macrophage Activation Syndrome in Adult-Onset Still's Disease.

    Leelaviwat N, Armin S, Mekraksakit P, Nugent K

    Cureus 2023; (15(4)):e37231 doi:10.7759/cureus.37231.

    PMID: 37162784

This page is for informational purposes only and does not replace professional medical advice. If you experience severe symptoms like constant fever, unusual bruising, or extreme confusion, seek emergency medical care immediately.

Get notified when new evidence is published on Adult-onset Still disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.